Vebreltinib在MET重排实体瘤中的抗肿瘤活性及临床基因组特征分析
在超过46,000例实体瘤的综合基因组分析中,致癌性MET重排约占0.04%。II期临床试验初步分析显示,在MET融合阳性实体瘤中,I型MET酪氨酸激酶抑制剂vebreltinib的客观缓解率为50%,疾病控制率为79%,在肺腺癌和肝内胆管癌等多种癌症类型中观察到抗肿瘤活性。与MET外显子14改变的肺癌类似,激酶结构域继发突变可导致MET融合阳性癌症对MET酪氨酸激酶抑制剂耐药。
要点
- 致癌性MET重排在超过46,000例实体瘤中约占0.04%。
- Vebreltinib在MET融合阳性实体瘤的II期试验中客观缓解率50%,疾病控制率79%。
- 激酶结构域继发突变可导致MET融合阳性癌症对MET酪氨酸激酶抑制剂耐药。
核心结论
- 这些数据将MET重排归类为实体瘤中的可操作靶点。
- MET融合是可用vebreltinib靶向的独特分子亚型癌症。
研究设计与样本
- 对超过46,000例实体瘤进行泛癌种综合基因组分析。
- 一项在MET融合阳性实体瘤中评估I型MET酪氨酸激酶抑制剂vebreltinib的II期临床试验的初步分析。
- 临床前建模。
主要发现
- 在超过46,000例实体瘤的综合基因组分析中,致癌性MET重排约占0.04%。
- II期临床试验初步分析显示,在MET融合阳性实体瘤中,客观缓解率为50%,疾病控制率为79%。
- 在包括肺腺癌和肝内胆管癌等多种癌症类型中观察到抗肿瘤活性。
- 与MET外显子14改变的肺癌类似,激酶结构域继发突变可导致MET融合阳性癌症对MET酪氨酸激酶抑制剂耐药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumor activity of MET inhibitors in MET rearrangement-positive cancers are limited. In this study, in a pan-cancer analysis of >46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic MET rearrangements in ∼0.04% of cancers. Preliminary analysis from a phase II clinical trial of the type I MET tyrosine kinase inhibitor (TKI) vebreltinib in MET fusion-positive solid tumors demonstrated an objective response rate of 50% and disease control rate of 79%, with antitumor activity seen in diverse cancer types, including lung adenocarcinoma and intrahepatic cholangiocarcinoma, among others. Similar to MET exon 14-altered lung cancer, secondary mutations in the kinase domain can confer resistance to MET TKIs in MET fusion-positive cancers. Overall, these data categorize MET rearrangements as actionable targets in solid tumors. SIGNIFICANCE: MET rearrangement-positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.
引用
- Nakazawa S, Pecci F, Odintsov I, et al. Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements. Cancer Discov. 2025. PMID: 40202082. doi:10.1158/2159-8290.CD-24-1726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。